2 Cash-Heavy Stocks with Exciting Potential and 1 We Ignore
2 Healthcare Stocks for Long-Term Investors and 1 We Brush Off
Therapeutics Stocks Q1 Teardown: BioMarin Pharmaceutical (NASDAQ:BMRN) Vs The Rest
Data from an investigator-led study showed treatment with VOXZOGO resulted in sustained improvements in growth over three years in children with hypochondroplasia
2 Profitable Stocks Worth Your Attention and 1 We Find Risky
Why BioMarin Pharmaceutical (BMRN) Stock Is Trading Up Today
1 Small-Cap Stock with Solid Fundamentals and 2 We Find Risky
Study met primary endpoint, exceeding expectations with a highly statistically significant improvement in annualized growth velocity (AGV, change from baseline) of 2.33 cm/yr compared to placebo at week...
ENERGY 3 study met 1 of 2 co-primary endpoints in children with ENPP1 deficiency
2 Cash-Producing Stocks Worth Investigating and 1 We Turn Down